232
Views
0
CrossRef citations to date
0
Altmetric
Review

Latanoprost, a balanced prostaglandin

, &
Pages 61-72 | Received 30 Sep 2018, Accepted 02 Jan 2019, Published online: 21 Jan 2019

References

  • Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367–1377.
  • Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82(11):887–888.
  • Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
  • International Council of Ophthalmology. Guidelines for Glaucoma Eye Care [Internet]. 2016. Available from: https://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf
  • Forsman E, Kivela T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma. 2007;16(3):313–319.
  • Leske MC. Open-angle glaucoma—an epidemiologic overview. Ophthalmic Epidemiol. 2007;14(4):166–172.
  • European Glaucoma Society. Terminology and Guidelines for Glaucoma [Internet]. Italy: Publicomm; 2014. Available from: http://www.eugs.org/eng/guidelines.asp
  • National Institute for Health and Care Excellence. Glaucoma: diagnosis and management [Internet]. 2009. Available from: https://www.nice.org.uk/guidance/cg85/resources/glaucoma-diagnosis-and-management-975690568645
  • Canadian Ophthalmological Society. Evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44(Suppl 1):S7–93.
  • Prum BE Jr., Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern(®) guidelines. Ophthalmology. 2016;123(1):P41–P111.
  • Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53(Suppl1):S107–120.
  • Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140.
  • Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13(5):723–745.
  • Bhosle MJ, Reardon G, Camacho FT, et al. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population. Am J Geriatr Pharmacother. 2007;5(2):100–111.
  • Hahn SR, Kotak S, Tan J, et al. Physicians’ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma. Curr Med Res Opin. 2010;26(4):957–963.
  • Lou H, Wang H, Zong Y, et al. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015;31(6):1139–1147.
  • Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967–1985.
  • Denis P. [Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study]. J Fr Ophtalmol. 2016;39(7):622–630.
  • Aptel F, Choudhry R, Stalmans I. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2016;32(8):1457–1463.
  • Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304.
  • Chen R, Yang K, Zheng Z, et al. Meta-analysis of the efficacy and safety of latanoprost monotherapy in patients with angle-closure glaucoma. J Glaucoma. 2016;25(3):e134–144.
  • Ikeda Y, Mori K, Tada K, et al. Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. Clin Ophthalmol. 2016;10:1633–1637.
  • Stalmans I, Oddone F, Cordeiro MF, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016;254(6):1151–1158.
  • Fogagnolo P, Dipinto A, Vanzulli E, et al. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Adv Ther. 2015;32(4):356–369.
  • Ge J, Li X, Sun X, et al. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]. Zhonghua Yan Ke Za Zhi. 2015;51(2):95–102.
  • Mishra D, Sinha BP, Kumar MS. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. Korean J Ophthalmol. 2014;28(5):399–407.
  • Konstas AG, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97(12):1510–1515.
  • Li J, Lin X, Yu M. Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. Eur J Ophthalmol. 2015;25(1):18–26.
  • Cucherat M, Stalmans I, Rouland JF. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014;23(1):e69–e75.
  • Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014;48(12):1585–1593.
  • Birt CM, Buys YM, Ahmed II, et al. Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). J Glaucoma. 2010;19(7):460–467.
  • Whitson JT. Travoprost—a new prostaglandin analogue for the treatment of glaucoma. Expert Opin Pharmacother. 2002;3(7):965–977.
  • Kitnarong N, Zhao Y, Netland PA, et al. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther. 2004;21(4):203–213.
  • Kara C, Sen EM, Elgin KU, et al. Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term? Int Ophthalmol. 2017;37(3):619–626.
  • Li X, He F, Gabelt BT, et al. Effects of latanoprost and bimatoprost on the expression of molecules relevant to ocular inflow and outflow pathways. PLoS One. 2016;11(3):e0151644.
  • Honrubia F, García-Sánchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93(3):316–321.
  • Crichton AC, Vold S, Williams JM, et al. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv Ther. 2013;30(3):260–270.
  • Muñoz Negrete FJ, Lemij HG, Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol. 2017;11:557–566.
  • Hommer A. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension. Drugs Today (Barc). 2010;46(6):409–416.
  • Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88(3):329–336.
  • Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97(2):196–200.
  • Weinreb RN, Brandt JD, Garway-Heath D, et al., editors. Intraocular pressure. World glaucoma association consensus series - 4 [internet]. The Netherlands: Kugler Publications; 2007.
  • Greig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging. 2015;32(3):251–260.
  • Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389.
  • Xing Y, Jiang FG, Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014;7(5):879–890.
  • Schwenn O, Heckmann B, Guzy C, et al. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol. 2010;10:21.
  • Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012;6:771–775.
  • Palmberg P, Kim EE, Kwok KK, et al. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010;20(4):708–718.
  • Lazaridou MN, Montgomery DM, Ho WO, et al. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr Med Res Opin. 2008;24(10):2725–2728.
  • Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128(2):165–172.
  • Varma R, Hwang LJ, Grunden JW, et al. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy. Br J Ophthalmol. 2010;94(1):80–84.
  • Liu AW, Gan LY, Yao X, et al. Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. Int J Ophthalmol. 2016;9(5):750–756.
  • Guven Yilmaz S, Degirmenci C, Karakoyun YE, et al. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018;38(4):1425-1431.
  • Pachimkul P, Yuttitham K, Thoophom P. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. J Med Assoc Thai. 2011;94(Suppl 2):S81–87.
  • Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009;19(1):66–71.
  • Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22(1):5–18.
  • Cheng JW, Cheng SW, Gao LD, et al. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079.
  • Inoue K, Okayama R, Higa R, et al. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination. J Ocul Pharmacol Ther. 2011;27(6):581–587.
  • Igarashi R, Togano T, Sakaue Y, et al. Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timolol fixed combinations in patients with normal-tension glaucoma. J Ophthalmol. 2014;2014:720385.
  • Konstas AG, Quaranta L, Bozkurt B, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33(4):481–517.
  • Konstas AG, Boboridis KG, Kapis P, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017;34(1):221–235.
  • Konstas AG, Voudouragkaki IC, Boboridis KG, et al. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014;31(6):592–603.
  • Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol. 2008;92(9):1227–1231.
  • Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112(2):262–266.
  • Cherecheanu AP, Garhofer G, Schmidl D, et al. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol. 2013;13(1):36–42.
  • Rossetti L, Sacchi M, Karabatsas CH, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthalmol. 2015;15:7.
  • Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917–2923.
  • Koz OG, Ozsoy A, Yarangumeli A, et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand. 2007;85(8):838–843.
  • Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the glaucoma adherence and persistency study. Ophthalmology. 2007;114(9):1599–1606.
  • Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. J Ocul Pharmacol Ther. 2009;25(6):555–561.
  • Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25(2):145–152.
  • Reardon G, Schwartz GF, Kotak S. Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. BMC Ophthalmol. 2010;10:5.
  • Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Exp Ophthalmol. 2007;35(7):602–611.
  • Orme M, Collins S, Dakin H, et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010;26(3):511–528.
  • Beckers HJ, Schouten JS, Webers CA, et al. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1485–1490.
  • Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007;24(2):376–386.
  • Schmidl D, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31(2):63–77.
  • Harasymowycz P, Birt C, Gooi P, et al. Medical management of glaucoma in the 21st century from a Canadian perspective. J Ophthalmol. 2016;2016:6509809.
  • Nordmann JP, Auzanneau N, Ricard S, et al. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1:75.
  • Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058.
  • Guedes RA, Guedes VM, Freitas SM, et al. Quality of life of glaucoma patients under medical therapy with different prostaglandins. Clin Ophthalmol. 2012;6:1749–1753.
  • Weng Y, Liu J, Jin S, et al. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B. 2017;7(3):281–291.
  • Kim J, Kudisch M, Da Silva NRK, et al. Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent. J Control Release. 2018;269:45–51.
  • Xie J, Wang C, Ning Q, et al. A new strategy to sustained release of ocular drugs by one-step drug-loaded microcapsule manufacturing in hydrogel punctal plugs. Graefes Arch Clin Exp Ophthalmol. 2017;255(11):2173–2184.
  • Kinoshita S, Ohguchi T, Noda K, et al. Evaluation of the safety and tolerability of conjunctival ring for posterior segment of the eye. Curr Eye Res. 2017;42(8):1149–1154.
  • Cavet ME, DeCory HH. The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1-2):52-60.
  • Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017;18(4):433–444.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.